# Pfizer Inc. (PFE) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $30.00, market value $171.0 billion.

## Valuation
- **P/E (trailing): 42.9×** (5-yr avg 23.7×, 3-yr avg 33.0×). Pfizer Inc. trades at 42.9× trailing earnings, well above its own five-year average of 23.7×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 10.3×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 2.7×**. Each dollar of revenue is priced at 2.7×.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 6.4%** (5-yr avg 8.0%). Free cash flow equals 6.4% of the market value, in line with its five-year average of 8.0%. Above 5% is generally attractive.
- **Earnings yield: 2.3%**. The inverse of the P/E: 2.3% of the price is earned each year.

## Profitability
- **Net margin: 12.4%**. 12.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 9.0%**. 9.0% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: 2.1%**. Each dollar of assets produces 2.1% of profit.

## Growth
- **Revenue growth (1 yr): -1.6%** (3-yr -12.0%/yr, 5-yr 8.5%/yr). Revenue fell 1.6% over the last year, against 8.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -3.5%** (3-yr -37.1%/yr, 5-yr -3.6%/yr). Earnings per share fell 3.5%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): -29.6%/yr**. Free cash flow has compounded at -29.6% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.75**. Debt is 0.75 times equity, moderate leverage.
- **Current ratio: 1.16** (quick 1.16). Current assets cover the next year's liabilities 1.16 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 5.73%** ($1.72 per share, trailing). Pfizer Inc. yields 5.73%, an income-level yield.
- **Payout ratio: 126%**. The dividend exceeds earnings (126% payout), which is rarely sustainable outside REITs and one-off years.
- **Consecutive years of increases: 15**. 15 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 3.6%/yr** (1-yr 2.4%). The dividend has grown 3.6% a year over five years.

## Analyst view
- **Analyst consensus: buy** (26 analysts). 26 analysts cover Pfizer Inc.; the consensus is buy, with an average price target of $29.26 (-2% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 33.1%** (YTD 29.5%, 3-mo 22.5%). The shares are up 33.1% over twelve months including dividends.
- **From 52-week high: -3.4%** (27.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 68**. An RSI of 68 is neutral.
- **Beta (1 yr): 0.26** (volatility 21%). Beta of 0.26 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PFE · Page: https://foliofundamentals.com/stocks/pfe

Not investment advice.